# rs56007086 and Breast cancer (16q12)

Configuration `no_qbic`, named mode, seed 0. Models: generator openai/gpt-6-luna, critic openai/gpt-6-luna, summariser openai/gpt-6-luna. Cost $0.01 over 9 model calls; 186 s.

Variant `chr16:52565398:G>A` (germline); expression context: DepMap:ACH-000019 (MCF7).

## Ranked chains

### 1. H0: Null: no TF-mediated effect of rs56007086 (p = 0.50)

Null chain: no TF-mediated effect of this variant.

Predictions: The variant will show no reproducible allele-dependent TF occupancy that explains a target-gene expression effect.; Isogenic editing will not produce a reproducible TF-dependent expression change; any disease association, if present, could reflect another variant or another mechanism.

Falsified if: Isogenic editing reproducibly changes target-gene expression and the effect depends on a specific TF whose occupancy at the site is allele-dependent.

### 2. H1: FOXA1-dependent effect at a candidate TOX3 regulatory region (p = 0.22)

TF FOXA1 (QBiC-SELEX coverage own_model), ref allele binds more; element Intronic CASC16 sequence annotated with an enhancer feature; the nearest ENCODE dELS cCRE is 38 bp away and does not overlap the variant.; gene TOX3; cell type MCF7.

| Step | Claim | Status | Evidence |
| --- | --- | --- | --- |
| binding | FOXA1 is a candidate because it has five MCF-7 ChIP-seq peaks containing the variant and is highly expressed there. Ref G is entered as a provisional direction only to make this chain testable; no QBiC-SELEX result or allele-specific evidence supports ref over alt, so the actual binding direction is unknown. FOXA1 is prioritized among the many bound TFs because its MCF-7 occupancy is repeatedly reported in this context. | weak | [E04](#e04), [E05](#e05) |
| element | The site is intronic in CASC16 and has an enhancer-feature annotation, but the nearby ENCODE dELS cCRE does not overlap it; enhancer activity at the variant has not been functionally demonstrated. | supported | [E01](#e01), [E03](#e03) |
| gene | TOX3 is a candidate target because its TSS is 17.6 kb away, but no evidence links this site to TOX3 regulation. No significant GTEx eQTL is reported for this variant, including in breast mammary tissue. | supported | [E02](#e02), [E17](#e17), [E19](#e19) |
| cell_type | MCF-7 is a relevant context for this candidate because FOXA1 occupancy over the variant and high FOXA1 expression are reported there. | supported | [E05](#e05) |
| phenotype | TOX3 has breast-cancer gene-level context, but the supplied literature concerns other variants or candidate loci and does not establish a role for rs56007086 in breast cancer. | supported | [E18a](#e18a), [E18b](#e18b), [E21](#e21) |

Predictions: Allele-specific FOXA1 occupancy at the site should be detectable if this chain is correct; ref is the provisional test direction, not an evidence-supported result.; An isogenic G-to-A edit should alter TOX3 expression in MCF-7, and the effect should be reduced by FOXA1 depletion or disruption of FOXA1 binding at the site.

Falsified if: A sensitive allele-specific assay finds no FOXA1 occupancy difference or finds greater occupancy with alt A, and isogenic editing produces no FOXA1-dependent change in TOX3 expression.

### 3. H2: GATA3-dependent effect at a candidate TOX3 regulatory region (p = 0.20)

TF GATA3 (QBiC-SELEX coverage own_model), ref allele binds more; element Intronic CASC16 sequence annotated with an enhancer feature; the nearest ENCODE dELS cCRE is 38 bp away and does not overlap the variant.; gene TOX3; cell type MCF7.

| Step | Claim | Status | Evidence |
| --- | --- | --- | --- |
| binding | GATA3 is a candidate because it has four MCF-7 ChIP-seq peaks containing the variant and is highly expressed there. Ref G is entered as a provisional direction only to make this chain testable; no QBiC-SELEX result or allele-specific evidence supports ref over alt, so the actual binding direction is unknown. Its MCF-7 occupancy and expression make it a plausible alternative to FOXA1, not a proven mediator. | weak | [E04](#e04), [E06](#e06) |
| element | The site is intronic in CASC16 and has an enhancer-feature annotation, but the nearby ENCODE dELS cCRE does not overlap it; enhancer activity at the variant has not been functionally demonstrated. | supported | [E01](#e01), [E03](#e03) |
| gene | TOX3 is a candidate target because its TSS is 17.6 kb away, but no evidence links this site to TOX3 regulation. No significant GTEx eQTL is reported for this variant, including in breast mammary tissue. | supported | [E02](#e02), [E17](#e17), [E19](#e19) |
| cell_type | MCF-7 is a relevant context for this candidate because GATA3 occupancy over the variant and high GATA3 expression are reported there. | supported | [E06](#e06) |
| phenotype | TOX3 has breast-cancer gene-level context, but the supplied literature concerns other variants or candidate loci and does not establish a role for rs56007086 in breast cancer. | supported | [E18a](#e18a), [E18b](#e18b), [E21](#e21) |

Predictions: Allele-specific GATA3 occupancy at the site should be detectable if this chain is correct; ref is the provisional test direction, not an evidence-supported result.; An isogenic G-to-A edit should alter TOX3 expression in MCF-7, and the effect should be reduced by GATA3 depletion or disruption of GATA3 binding at the site.

Falsified if: A sensitive allele-specific assay finds no GATA3 occupancy difference or finds greater occupancy with alt A, and isogenic editing produces no GATA3-dependent change in TOX3 expression.

### 4. H3: SPDEF-dependent effect at a candidate TOX3 regulatory region (p = 0.08)

TF SPDEF (QBiC-SELEX coverage own_model), ref allele binds more; element Intronic CASC16 sequence annotated with an enhancer feature; the nearest ENCODE dELS cCRE is 38 bp away and does not overlap the variant.; gene TOX3; cell type MCF7.

| Step | Claim | Status | Evidence |
| --- | --- | --- | --- |
| binding | SPDEF is a lower-priority candidate because one MCF-7 ChIP-seq peak contains the variant and SPDEF is expressed there. Ref G is entered as a provisional direction only to make this chain testable; no QBiC-SELEX result or allele-specific evidence supports ref over alt, so the actual binding direction is unknown. | weak | [E04](#e04), [E07](#e07) |
| element | The site is intronic in CASC16 and has an enhancer-feature annotation, but the nearby ENCODE dELS cCRE does not overlap it; enhancer activity at the variant has not been functionally demonstrated. | supported | [E01](#e01), [E03](#e03) |
| gene | TOX3 is a candidate target because its TSS is 17.6 kb away, but no evidence links this site to TOX3 regulation. No significant GTEx eQTL is reported for this variant, including in breast mammary tissue. | supported | [E02](#e02), [E17](#e17), [E19](#e19) |
| cell_type | MCF-7 is a relevant context for this candidate because SPDEF occupancy over the variant and SPDEF expression are reported there. | supported | [E07](#e07) |
| phenotype | TOX3 has breast-cancer gene-level context, but the supplied literature concerns other variants or candidate loci and does not establish a role for rs56007086 in breast cancer. | supported | [E18a](#e18a), [E18b](#e18b), [E21](#e21) |

Predictions: Allele-specific SPDEF occupancy at the site should be detectable if this chain is correct; ref is the provisional test direction, not an evidence-supported result.; An isogenic G-to-A edit should alter TOX3 expression in MCF-7, and the effect should be reduced by SPDEF depletion or disruption of SPDEF binding at the site.

Falsified if: A sensitive allele-specific assay finds no SPDEF occupancy difference or finds greater occupancy with alt A, and isogenic editing produces no SPDEF-dependent change in TOX3 expression.

## Prediction matrix

| Test | Cost | Separates top two | H0 | H1 | H2 | H3 |
| --- | --- | --- | --- | --- | --- | --- |
| Targeted allele-specific CUT&RUN-qPCR for FOXA1, GATA3, and SPDEF at the site in MCF-7, with alleles distinguished by sequence reads. | low | yes | No reproducible allelic occupancy imbalance that supports a TF-mediated effect is found. | A reproducible allelic occupancy imbalance is found for FOXA1; the direction is measured rather than assumed. | A reproducible allelic occupancy imbalance is found for GATA3; the direction is measured rather than assumed. | A reproducible allelic occupancy imbalance is found for SPDEF; the direction is measured rather than assumed. |
| Create isogenic G and A MCF-7 cells, measure TOX3 and nearby-gene expression, and repeat after individual FOXA1, GATA3, or SPDEF depletion. | high | yes | Editing produces no reproducible TF-dependent expression change. | Editing changes TOX3 expression, and the change is reduced by FOXA1 depletion more than by GATA3 or SPDEF depletion. | Editing changes TOX3 expression, and the change is reduced by GATA3 depletion more than by FOXA1 or SPDEF depletion. | Editing changes TOX3 expression, and the change is reduced by SPDEF depletion more than by FOXA1 or GATA3 depletion. |

## Next experiment

Perform targeted allele-specific CUT&RUN-qPCR for FOXA1 and GATA3 at the variant in MCF-7 cells, measuring rather than presuming the direction of any allelic imbalance. This is the lowest-cost proposed test that distinguishes the top two chains; it tests allele-sensitive occupancy, not by itself a causal effect on TOX3.

## Investigate calls

- eqtl_lookup({"tissue": "Breast Mammary Tissue"})
- literature_search({"query": "rs56007086 breast cancer TOX3"})
- gene_disease({"gene": "TOX3"})

## Flags

- literature_fallback: no hits for 'rs56007086 AND TOX3 AND "breast cancer"'; dropped the rsID

Citation support: 1.00 of links cite only evidence that passed every check.

## Evidence

<a id="e01"></a>**E01** variant_annotation, Ensembl VEP (GRCh38) (https://rest.ensembl.org/vep/human/region/16:52565398-52565398:1/A?content-type=application/json&Conservation=1; retrieved 2026-10-26T02:25:34+00:00)

> Variant chr16:52565398:G>A (GRCh38), allele string G/A
> Known IDs: rs56007086
> Most severe consequence: intron_variant
> Regulatory features: ENSR16_9QTBS enhancer
> GERP conservation score at the site: -4.73
> Transcript consequences: CASC16 (intron_variant, non_coding_transcript_variant)

<a id="e02"></a>**E02** nearest_genes, Ensembl overlap (protein_coding) (https://rest.ensembl.org/overlap/region/human/16:51565398-53565398?feature=gene;biotype=protein_coding;content-type=application/json; retrieved 2026-10-26T02:25:46+00:00)

> 6 protein-coding genes within 1000 kb of chr16:52565398:G>A, by distance to TSS:
> TOX3: 17.6 kb from TSS (upstream, strand -1)
> CHD9NB: 487.5 kb from TSS (downstream, strand -1)
> CHD9: 489.6 kb from TSS (upstream, strand +1)
> RBL2: 868.6 kb from TSS (upstream, strand +1)
> AKTIP: 939.0 kb from TSS (downstream, strand -1)
> HNRNPA1L3: 1012.0 kb from TSS (downstream, strand +1)

<a id="e03"></a>**E03** ccre_lookup, ENCODE v4 cCRE registry (ENCFF420VPZ) and SCREEN (https://screen-beta-api.wenglab.org/dataws/cre_table; retrieved 2026-10-26T02:25:06+00:00)

> No cCRE overlaps the variant; nearest is EH38E3180851 (dELS) 38 bp away.
> SCREEN: 1 cCREs within 500 bp (max z-score across ENCODE biosamples):
> EH38E3180851 dELS: DNase z 4.2, H3K27ac z 6.1, H3K4me3 z 1.8, CTCF z 1.9; nearby genes CASC16, TOX3, AC026462.5
> Biosample-specific z-scores are not in this call; the values above are maxima over biosamples.

<a id="e04"></a>**E04** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> ENCODE TF ChIP-seq at chr16:52565398:G>A: 215 peaks contain the variant, from 162 factors in 7 biosamples. In the matching biosample MCF-7: 16 peaks from 11 factors. No cCRE contains the variant. Bound factors outside the TF model collection (co-factors, Pol II, and TFs with no binding model; signs of an active element, not TF candidates): ARID4A, ARID5B, ASH2L, BCL3, CBX5, CHD4, CTBP1, EP300, GATAD1, GZF1, HBP1, HDAC1 (+51 more). Bound, expressed TFs with a binding model: 79; listed one per row: FOXA1, GATA3, SPDEF, NR2F2, CEBPB, TCF7L2, MYBL2, SP1, YY1, MAX; also bound: JUND, GATAD2A, BHLHE40, ZGPAT, RXRA, ZNF609, RXRB, ZNF770, FOXP4, AHDC1, GMEB1, ZNF772, ZNF788P, HMG20B, ELF1, ELF3, RELA, TBX2, ERF, HMG20A, CREB1, MBD1, ATF1, CREM, FOSL2, THAP11, SOX13, MEF2A, ZNF703, FOXJ3 (+39 more). Bound but below 1 TPM: DLX6, ETS1, FOXA2, FOXA3, GFI1, HLF, HNF1A, HNF1B, HNF4A, MAFF. Assayed with no peak here: 49 TFs in the matching biosample, 425 only elsewhere; never assayed: 536.

<a id="e05"></a>**E05** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> FOXA1: bound here. 5 ENCODE ChIP-seq peak(s) contain the variant, in the matching biosample MCF-7; also in A549, HepG2, liver (e.g. ENCSR126YEB). 88.38 TPM in DepMap:ACH-000019 (MCF7), rank 28 of 1626 TFs.

<a id="e06"></a>**E06** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> GATA3: bound here. 4 ENCODE ChIP-seq peak(s) contain the variant, in the matching biosample MCF-7 (e.g. ENCSR000EWV). 346.04 TPM in DepMap:ACH-000019 (MCF7), rank 5 of 1626 TFs.

<a id="e07"></a>**E07** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> SPDEF: bound here. 1 ENCODE ChIP-seq peak(s) contain the variant, in the matching biosample MCF-7 (e.g. ENCSR042GSX). 72.51 TPM in DepMap:ACH-000019 (MCF7), rank 40 of 1626 TFs.

<a id="e08"></a>**E08** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> NR2F2: bound here. 1 ENCODE ChIP-seq peak(s) contain the variant, in the matching biosample MCF-7 (e.g. ENCSR000BUY). 38.14 TPM in DepMap:ACH-000019 (MCF7), rank 103 of 1626 TFs.

<a id="e09"></a>**E09** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> CEBPB: bound here. 1 ENCODE ChIP-seq peak(s) contain the variant, in the matching biosample MCF-7 (e.g. ENCSR000BSR). 24.33 TPM in DepMap:ACH-000019 (MCF7), rank 169 of 1626 TFs.

<a id="e10"></a>**E10** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> TCF7L2: bound here. 1 ENCODE ChIP-seq peak(s) contain the variant, in the matching biosample MCF-7 (e.g. ENCSR000EWT). 4.89 TPM in DepMap:ACH-000019 (MCF7), rank 642 of 1626 TFs.

<a id="e11"></a>**E11** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> MYBL2: bound elsewhere. 4 ENCODE ChIP-seq peak(s) contain the variant, only in other biosamples: HepG2 (e.g. ENCSR581KCO). 49.2 TPM in DepMap:ACH-000019 (MCF7), rank 66 of 1626 TFs.

<a id="e12"></a>**E12** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> SP1: bound elsewhere. 4 ENCODE ChIP-seq peak(s) contain the variant, only in other biosamples: A549, liver (e.g. ENCSR000BPE). 33.01 TPM in DepMap:ACH-000019 (MCF7), rank 122 of 1626 TFs.

<a id="e13"></a>**E13** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> YY1: bound elsewhere. 3 ENCODE ChIP-seq peak(s) contain the variant, only in other biosamples: liver (e.g. ENCSR382MOM). 61.08 TPM in DepMap:ACH-000019 (MCF7), rank 48 of 1626 TFs.

<a id="e14"></a>**E14** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> MAX: bound elsewhere. 2 ENCODE ChIP-seq peak(s) contain the variant, only in other biosamples: liver (e.g. ENCSR521IID). 76.95 TPM in DepMap:ACH-000019 (MCF7), rank 35 of 1626 TFs.

<a id="e15"></a>**E15** gwas_lookup, GWAS Catalog REST v2 (https://www.ebi.ac.uk/gwas/rest/api/v2/associations?rs_id=rs56007086&size=100; retrieved 2026-10-26T02:25:35+00:00)

> 0 GWAS Catalog associations for rs56007086, strongest first:

<a id="e16"></a>**E16** finemap_lookup, Open Targets Platform (https://api.platform.opentargets.org/api/v4/graphql; retrieved 2026-10-26T02:25:34+00:00)

> Open Targets has no record of 16_52565398_G_A.

<a id="e17"></a>**E17** eqtl_lookup, GTEx Portal API v2 (gtex_v8) (https://gtexportal.org/api/v2/association/singleTissueEqtl?variantId=chr16_52565398_G_A_b38&datasetId=gtex_v8; retrieved 2026-10-26T02:27:56+00:00)

> 0 significant GTEx v8 single-tissue eQTLs for chr16_52565398_G_A_b38. NES is the effect of the alt allele (A) relative to ref (G).

<a id="e18"></a>**E18** literature_search, Europe PMC REST (https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TOX3%20AND%20%22breast%20cancer%22&format=json&pageSize=8&resultType=core; retrieved 2026-10-26T02:25:47+00:00)

> Europe PMC: 586 hits for 'TOX3 AND "breast cancer"'; top 7 with PMIDs:
> PMID 41230718 (2026): Cis-regulatory and long noncoding RNA alterations in breast cancer - current insights, biomarker utility, and the critical need for functional validation.
> PMID 41849381 (2026): A transcription regulator atlas identifies TOX3 as an Atoh1 coactivator in cerebellar development and tumorigenesis.
> PMID 41595182 (2026): Identification and Characterisation of Canine Osteosarcoma Biomarkers and Therapeutic Targets.
> PMID 41596432 (2026): Bone Metastasis in Estrogen Receptor-Positive Breast Cancer: Molecular Insights and Therapeutic Advances.
> PMID 40932605 (2025): Molecular signatures of breast cancer in the Iranian population: a review of cell growth and cell cycle regulators.
> PMID 42700350 (2026): Interactions between circular RNAs (circRNAs) and the Hippo pathway in cancer.
> PMID 41871294 (2026): A reanalysis of a genome-wide association study on breast cancer in Asian populations using the SG10K_Health reference panel for imputation: a multi-Centre case-control analysis.

<a id="e18a"></a>**E18a** literature_search, Europe PMC abstract, PMID 41230718 (https://europepmc.org/article/MED/41230718; retrieved 2026-10-26T02:25:47+00:00)

> Key examples include promoter mutations [e.g., rs2279744 (Mouse double minute 2 homolog gene; MDM2)], enhancer mutations [e.g., rs4784227 (thymocyte selection-associated high mobility group box family member 3 gene; TOX3)], and lncRNAs [e.g., HOX transcript antisense intergenic RNA (HOTAIR)] linked to progression, metastasis, and poor survival.

<a id="e18b"></a>**E18b** literature_search, Europe PMC abstract, PMID 41871294 (https://europepmc.org/article/MED/41871294; retrieved 2026-10-26T02:25:47+00:00)

> Differences in panel performance influenced association signals, including breast cancer candidate loci such as FGFR2, TOX3, and ESR1.

<a id="e19"></a>**E19** eqtl_lookup, GTEx Portal API v2 (gtex_v8) (https://gtexportal.org/api/v2/association/singleTissueEqtl?variantId=chr16_52565398_G_A_b38&datasetId=gtex_v8; retrieved 2026-10-26T02:27:56+00:00)

> 0 significant GTEx v8 single-tissue eQTLs for chr16_52565398_G_A_b38 in tissues matching 'Breast Mammary Tissue'. NES is the effect of the alt allele (A) relative to ref (G).

<a id="e20"></a>**E20** literature_search, Europe PMC REST (https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=rs56007086%20breast%20cancer%20TOX3&format=json&pageSize=8&resultType=core; retrieved 2026-10-26T13:30:52+00:00)

> Europe PMC: 0 hits for 'rs56007086 breast cancer TOX3'; top 0 with PMIDs:

<a id="e21"></a>**E21** gene_disease, Open Targets Platform (https://api.platform.opentargets.org/api/v4/graphql; retrieved 2026-10-26T02:34:32+00:00)

> Open Targets: TOX3 and breast cancer (MONDO_0007254), overall score 0.58; by evidence type: genetic_association 0.91, literature 0.89
